



# Bi-Lobar Resin Y90 for Pancreatic NET

## Dr. Zachary T. Berman

Associate Clinical Professor of Radiology  
University of California, San Diego  
San Diego, CA



This presentation reflects Dr. Berman's clinical experience with the TriNav<sup>®</sup> Infusion System. Dr. Berman is a consultant for TriSalus<sup>™</sup> Life Sciences and has been compensated for this content. Results are not predictive of outcomes in other cases.




# Case Description


- 56-year-old male with grade 3 pancreatic neuroendocrine tumor
- Treated both lobes with resin Y90 microspheres, 1-month apart
  - Left lobe treated with TriNav Infusion System
  - Right lobe treated with traditional microcatheter (could not use TriNav on right due to vessel size)

# Cone Beam CT

Right Lobe via Traditional Microcatheter



Left Lobe via TriNav




Similar distribution of tumors on right and left, both multifocal and randomly distributed, with a relatively equal number of tumors in each lobe


# Left Lobe Cone Beam CT

Imaging acquired ~5 mins apart using same catheter placement and same injection parameters

Traditional Microcatheter




TriNav



Increased tumoral perfusion and decreased enhancement of the background liver with TriNav


# SPECT

Traditional Microcatheter  
Right Lobe Treatment




Dose delivered to entire region w/  
high background liver dose  
(↓ T:N ratio)

TriNav  
Left Lobe Treatment



Targeted delivery to tumors w/  
low background liver dose  
(↑ T:N ratio)

# Follow-Up MRI



A complete response on both sides; however, in the right lobe that was treated with a traditional microcatheter there is significant background parenchymal diffusion intensity, correlating with fibrotic reaction to the radiation.

In the left lobe that was treated with TriNav, there is no abnormal diffusion seen in the normal liver.



## Indications For Use

The TriNav<sup>®</sup> and TriNav<sup>®</sup> LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.<sup>1,2</sup>

## Contraindications

The TriNav<sup>®</sup> and TriNav<sup>®</sup> LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).<sup>1,2</sup>

**Rx Only** For the safe and proper use of TriNav<sup>®</sup> and TriNav<sup>®</sup> LV, refer to their individual Instructions for Use.

This content is sponsored by TriSalus Life Sciences<sup>®</sup>. Results are not predictive of outcomes in other cases.

1. TriSalus<sup>™</sup> TriNav<sup>®</sup> Infusion System, Instructions for Use  
2. TriSalus<sup>™</sup> TriNav<sup>®</sup> LV Infusion System, Instructions for Use

